Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Knight Therapeutics Inc.    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
5.4(c) 5.35(c) 5.25(c) 5.38(c) 5.51(c) Last
194 325 225 926 344 871 272 758 373 504 Volume
+0.37% -0.93% -1.87% +2.48% +2.42% Change
More quotes
Financials
Sales 2020 192 M 151 M 151 M
Net income 2020 30,9 M 24,2 M 24,2 M
Net Debt 2020 - - -
P/E ratio 2020 23,3x
Yield 2020 -
Sales 2021 206 M 162 M 162 M
Net income 2021 6,04 M 4,74 M 4,74 M
Net Debt 2021 - - -
P/E ratio 2021 148x
Yield 2021 -
Capitalization 717 M 563 M 562 M
Capi. / Sales 2020 3,72x
Capi. / Sales 2021 3,48x
Nbr of Employees 49
Free-Float 82,2%
More Financials
Company
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol. 
Sector
Pharmaceuticals
Calendar
03/18Earnings Release
More about the company
Notations Surperformance© of Knight Therapeutics Inc.
Trading Rating : Investor Rating :
More Ratings
All news about KNIGHT THERAPEUTICS INC.
2020KNIGHT THERAPEUTICS : Files Final Base Shelf Prospectus
MT
2020GFL ENVIRONMENTAL AND KNIGHT THERAPE : GFL Will Be Added To, Knight Deleted From..
MT
2020KNIGHT THERAPEUTICS : S&P Dow Jones Indices Announces Changes to the S&P/TSX Com..
AQ
2020KNIGHT THERAPEUTICS : Reports Third Quarter 2020 Results
AQ
2020Knight Therapeutics Reports Third Quarter 2020 Results
GL
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' Third Quarter 2020 Results ..
AQ
2020Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
GL
2020KNIGHT THERAPEUTICS : Signs New Exclusive AmBisome® Agreement with Gilead in Bra..
AQ
2020Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil
GL
2020KNIGHT THERAPEUTICS : and Therapeutics MD Announce Health Canada Approval of BIJ..
AQ
2020KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Health Canada Approval of BIJU..
AQ
2020Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
GL
2020KNIGHT THERAPEUTICS : Announces Filling of Supplement to a New Drug Submission f..
AQ
2020Knight Therapeutics Announces Filling of Supplement to a New Drug Submission ..
GL
2020KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Health Canada Approval of IMVE..
AQ
More news
News in other languages on KNIGHT THERAPEUTICS INC.
2020Knight annonce le dépôt d'un prospectus préalable de base simplifié final
2020Knight annonce le dépôt d'un prospectus préalable de base simplifié
2020KNIGHT THERAPEUTICS INC. : publication des résultats trimestriels
2020KNIGHT THERAPEUTICS INC. : Veröffentlichung des Quartalsergebnisses
2016KNIGHT THERAPEUTICS INC : publication des résultats annuels
More news
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | GUD | CA4990531069 | MarketScreener
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 7,19 CAD
Last Close Price 5,51 CAD
Spread / Highest target 45,2%
Spread / Average Target 30,6%
Spread / Lowest Target -0,18%
EPS Revisions
Managers and Directors
NameTitle
Jonathan Ross Goodman Chief Executive Officer & Director
Samira Sakhia President & Director
James Charles Gale Chairman
Utchanah Arvind Chief Financial Officer
Robert N. Lande Independent Director
Sector and Competitors